Since PD-1/PD-L1 blockades do not significantly promote global survivor in patients with recurrent GBM compared with standard therapy, clinical trials are exploring association between anti-PD-1/PD-L1 mAb with standard radio/chemotherapy and bevacizumab or new therapies such as genetically engineered T cells and vaccines (39, 111, 112). This evidence concerns the gene CD274 and glioblastoma.